Cerqueti Piera M, Saccà Sergio C, Allegri P, Ciurlo G, Zingirian M, Buscaglia S, Ciprandi G
Institute of Clinica Oculistica, University of Genoa, Italy.
Allergol Immunopathol (Madr). 1993 May-Jun;21(3):107-10.
Since corticosteroids represent a fundamental tool in the treatment of uveitis, we evaluate the clinical efficacy and possible appearance of side effects of deflazacort, a new corticosteroid of third generation, versus prednisone at equiactive dosages. Sixty six patients suffering from recurring acute anterior uveitis (RAAU) and/or chronic anterior uveitis (CAU) were treated with deflazacort or alternatively prednisone in an "open" study. Clinical efficacy, ophthalmological parameters and haemato-bioassays were evaluated on admission and during the treatment period. All patients showed a complete remission of clinical signs and symptoms with both treatment and no statistically significant difference was evidenced between the studied groups. Concerning the possible appearance of side effects, the comparison between deflazacort and prednisone a statistically significant difference. These preliminary results are strongly encouraging and suggest further controlled studies on the employment of deflazacort in the treatment of uveitis.
由于皮质类固醇是治疗葡萄膜炎的基本药物，我们评估了第三代新型皮质类固醇地夫可特与泼尼松在等效剂量下的临床疗效及可能出现的副作用。在一项“开放”研究中，66例复发性急性前葡萄膜炎（RAAU）和/或慢性前葡萄膜炎（CAU）患者接受了地夫可特或泼尼松治疗。在入院时和治疗期间评估了临床疗效、眼科参数和血液生物学检测。两组治疗后所有患者的临床体征和症状均完全缓解，且研究组之间无统计学显著差异。关于可能出现的副作用，地夫可特和泼尼松之间存在统计学显著差异。这些初步结果非常令人鼓舞，并建议对地夫可特治疗葡萄膜炎的应用进行进一步的对照研究。
